Kwangdong and Moderna strengthen partnership

Evidence-based marketing

Activities to provide updated COVID-19 vaccine and medical information

Expanding position in the COVID-19 vaccine market with its own sales and marketing competitiveness

Kwangdong Pharmaceutical (CEO Choi Seong-won) announced on the 13th that it will begin full-scale activities to provide medical information to medical staff about Moderna's newly updated COVID-19 vaccine 'Spikevax X', which was recently approved by the Ministry of Food and Drug Safety.

 

Moderna's monovalent vaccine against the XBB.1.5 mutation contains neutralizing antibodies against prevalent mutations such as BA.2.86, EG.5, and FL.1.5.1, as well as the Clinical data confirming the response has been published.

 

The vaccine approved this time is for those 12 years of age or older, and is strongly recommended for the elderly, those with weakened immune systems, and members of facilities vulnerable to infection.

 

Kwangdong plans to engage in various activities to provide product information on Spikevax The plan is to expand its position in the coronavirus vaccine market based on its own sales and marketing competitiveness.

 

Previously, health authorities decided to use the FDA-recommended XBB.1.5 target vaccine for fall/winter vaccination due to the prevalence of the Recently, the World Health Organization (WHO) emphasized the need for vaccination in winter, citing the increase in hospitalizations of COVID-19-infected people in Europe and other countries.

 

An official from Kwangdong Pharmaceutical said, “Moderna's COVID-19 vaccine is a vaccine that has proven excellent protective effect and safety in all age groups, including the elderly, immunocompromised, and those with underlying diseases through clinical trials and actual use evidence (single-use vial formulation) “The advantage is that it is manufactured with an increased ease of vaccination at medical institutions.” Meanwhile, Kwangdong Pharmaceutical established a relationship with Moderna, starting with a vaccine partnership in November last year.

 

This is the first case where Moderna has signed a business partnership agreement with a local pharmaceutical company, and the industry says that the sales power that Kwangdong Pharmaceutical has built based on collaboration with multinational pharmaceutical companies has shone.

 

Over the past 10 years since its establishment, Moderna has transformed from a research company that led the advancement of mRNA technology to a company with a diverse portfolio of clinical trials for vaccines and treatments.

 

Based on mRNA platform technology, 43 research and development programs are underway in the fields of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases.